JP2023510270A5 - - Google Patents

Info

Publication number
JP2023510270A5
JP2023510270A5 JP2022542003A JP2022542003A JP2023510270A5 JP 2023510270 A5 JP2023510270 A5 JP 2023510270A5 JP 2022542003 A JP2022542003 A JP 2022542003A JP 2022542003 A JP2022542003 A JP 2022542003A JP 2023510270 A5 JP2023510270 A5 JP 2023510270A5
Authority
JP
Japan
Prior art keywords
composition according
activin
antibody
sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022542003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510270A (ja
JP7802672B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/012598 external-priority patent/WO2021142191A1/en
Publication of JP2023510270A publication Critical patent/JP2023510270A/ja
Publication of JP2023510270A5 publication Critical patent/JP2023510270A5/ja
Priority to JP2025211378A priority Critical patent/JP2026031632A/ja
Application granted granted Critical
Publication of JP7802672B2 publication Critical patent/JP7802672B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022542003A 2020-01-08 2021-01-08 進行性骨化性線維異形成症の治療 Active JP7802672B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025211378A JP2026031632A (ja) 2020-01-08 2025-12-01 進行性骨化性線維異形成症の治療

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062958448P 2020-01-08 2020-01-08
US62/958,448 2020-01-08
US202063076691P 2020-09-10 2020-09-10
US63/076,691 2020-09-10
US202063081428P 2020-09-22 2020-09-22
US63/081,428 2020-09-22
PCT/US2021/012598 WO2021142191A1 (en) 2020-01-08 2021-01-08 Treatment of fibrodysplasia ossificans progressiva

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025211378A Division JP2026031632A (ja) 2020-01-08 2025-12-01 進行性骨化性線維異形成症の治療

Publications (3)

Publication Number Publication Date
JP2023510270A JP2023510270A (ja) 2023-03-13
JP2023510270A5 true JP2023510270A5 (enExample) 2024-01-16
JP7802672B2 JP7802672B2 (ja) 2026-01-20

Family

ID=74550734

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022542003A Active JP7802672B2 (ja) 2020-01-08 2021-01-08 進行性骨化性線維異形成症の治療
JP2025211378A Pending JP2026031632A (ja) 2020-01-08 2025-12-01 進行性骨化性線維異形成症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025211378A Pending JP2026031632A (ja) 2020-01-08 2025-12-01 進行性骨化性線維異形成症の治療

Country Status (12)

Country Link
US (2) US12344665B2 (enExample)
EP (1) EP4087652A1 (enExample)
JP (2) JP7802672B2 (enExample)
KR (1) KR20220139886A (enExample)
CN (1) CN115243763A (enExample)
AU (1) AU2021205929A1 (enExample)
BR (1) BR112022013589A2 (enExample)
CA (1) CA3164168A1 (enExample)
CL (1) CL2022001861A1 (enExample)
IL (1) IL294611B1 (enExample)
MX (1) MX2022008494A (enExample)
WO (1) WO2021142191A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235627A1 (en) * 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
WO1997042317A1 (en) 1996-05-07 1997-11-13 T Cell Sciences, Inc. APTAMERS FOR COMPLEMENT PROTEIN C3b
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
WO1999027133A1 (en) 1997-11-26 1999-06-03 Medical Research Council Improved selex procedure and an anti-cd4 aptamer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6180348B1 (en) 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000020040A1 (en) 1998-10-08 2000-04-13 University Of Massachusetts Controlling gene expression in living cells
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP4906094B2 (ja) 2004-01-16 2012-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レセプターを活性化し得る融合ポリペプチド
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
JP5270913B2 (ja) 2007-12-26 2013-08-21 サンゴバン・ティーエム株式会社 高電気抵抗高ジルコニア鋳造耐火物
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015152183A1 (ja) * 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
US9906799B2 (en) 2014-06-20 2018-02-27 Qualcomm Incorporated Copy from previous rows for palette mode coding
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva

Similar Documents

Publication Publication Date Title
AU784971B2 (en) Treatment of patients having non-Hodgkins lymphoma with bone marrow involvement with anti-CD20 antibodies
EP2417158B9 (en) Dkk-1 antibodies
US20240366756A1 (en) Combinations and uses thereof
US20200206228A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
KR102117202B1 (ko) 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
KR102241868B1 (ko) 항-cd38 항체 및 카르필조밉을 포함하는 조성물
AU2019234468B2 (en) Bispecific binding agents and uses thereof
US11224654B2 (en) Combinations and uses thereof
JP2014520784A (ja) 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用
AU2018221557B2 (en) Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination
JP2018533569A5 (enExample)
JP2024511281A5 (enExample)
CA2951427A1 (en) Treatment for chronic lymphocytic leukemia (cll)
CA3227172A1 (en) Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
US20240270862A1 (en) Use of b cell depleting agents for the treatment of rheumatic heart disease
WO2025072516A1 (en) Methods of reducing weight loss using anti-gdf15 antibodies
HK1162183A (en) Dkk-1 antibodies
HK1162183B (en) Dkk-1 antibodies
NZ617771B2 (en) Combination therapy with an anti - cd19 antibody and a purine analog
MXPA06011850A (en) Treatment of disorders